四川双马(000935) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥324,988,710.21, representing a 52.53% increase compared to ¥213,059,095.23 in the same period last year[5] - Net profit attributable to shareholders reached ¥116,549,153.25, a significant increase of 1,236.09% from ¥8,723,136.67 in the previous year[5] - The basic earnings per share rose to ¥0.15, marking a 1,400.00% increase from ¥0.01 in the same period last year[5] - Total operating revenue for the current period reached ¥324,988,710.21, a significant increase from ¥213,059,095.23 in the previous period, representing a growth of approximately 52.5%[23] - Net profit for the current period was ¥116,217,737.32, compared to ¥8,259,988.85 in the previous period, indicating a substantial increase of approximately 1,307.5%[24] - Total comprehensive income amounted to CNY 116,220,312.46, a significant increase from CNY 8,281,557.48 in the previous period[25] - Basic and diluted earnings per share both increased to CNY 0.15 from CNY 0.01[25] Assets and Liabilities - The company's total assets at the end of the reporting period were ¥9,030,246,383.08, a 0.43% increase from ¥8,991,376,516.63 at the end of the previous year[5] - The company's total assets amounted to ¥9,030,246,383.08, up from ¥8,991,376,516.63, reflecting a growth of about 0.4%[22] - Total liabilities decreased to ¥1,360,958,888.76 from ¥1,438,309,334.74, showing a reduction of approximately 5.4%[22] - The company's total liabilities decreased by 58.19% in other payables, amounting to ¥38,241,994.79, primarily due to dividend payments to shareholders[10] - The company's equity attributable to shareholders increased to ¥7,591,869,474.09 from ¥7,475,317,745.70, representing a growth of about 1.6%[22] Cash Flow - The company reported a net cash flow from operating activities of ¥38,529,015.68, which is a decrease of 26.71% compared to ¥52,573,281.08 in the same period last year[5] - Cash inflow from operating activities reached CNY 352,461,745.55, compared to CNY 189,337,069.31 in the prior period, reflecting an increase of approximately 86.2%[25] - Net cash flow from operating activities was CNY 38,529,015.68, down from CNY 52,573,281.08, indicating a decrease of about 26.7%[25] - Cash outflow for investing activities totaled CNY 19,758,234.35, significantly lower than CNY 710,797,749.80 in the previous period[26] - Net cash flow from investing activities was CNY 1,074,123.67, a recovery from a negative cash flow of CNY -125,260,564.83 in the prior period[26] - The company reported a net increase in cash and cash equivalents of CNY 33,739,556.42, contrasting with a decrease of CNY -75,045,017.00 in the prior period[26] Shareholder Structure - The largest shareholder, Beijing Harmony Hengyuan Technology Co., Ltd., holds 26.52% of shares, totaling 202,446,032 shares, with 124,005,100 shares pledged[17] - The second largest shareholder, LAFARGE CHINA OFFSHORE HOLDING COMPANY (LCOHC) LTD., owns 17.55% of shares, amounting to 133,952,761 shares[17] - Tianjin Saike Environmental Management Center (Limited Partnership) holds 10.24% of shares, which is 78,203,902 shares[17] - CITIC Financial Asset Management Co., Ltd. possesses 7.45% of shares, equating to 56,854,045 shares[17] - Zhongrong Life Insurance Co., Ltd. holds 6.80% of shares, totaling 51,919,170 shares[17] - The Basic Pension Insurance Fund No. 1003 holds 1.23% of shares, which is 9,414,734 shares[17] - The top ten shareholders collectively represent a significant portion of the company's equity, with the largest three shareholders alone accounting for over 54%[17] - The shareholder structure indicates a concentration of ownership, which may impact governance and strategic decisions[17] Research and Development - Research and development expenses increased to ¥14,741,288.49, reflecting a 100.00% increase as a result of the acquisition of Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.[13] - Research and development expenses for the current period were ¥14,741,288.49, compared to ¥0.00 in the previous period, indicating a new investment in innovation[23] Fair Value and Investment Income - The company reported a significant increase in fair value gains of ¥82,252,243.83, compared to a loss of ¥66,419,972.85 in the previous year[13] - The company’s investment income showed a loss of ¥23,203,645.78, an improvement from a loss of ¥31,795,847.80 in the previous year[13] Future Outlook - Future outlook includes plans for market expansion and potential new product launches, aiming to sustain growth momentum[23] Other Information - The company did not undergo an audit for the first quarter report[27] - The company is set to implement new accounting standards starting from 2025[28]